Warranty period for low risk positron emission tomography for detection of cardiac allograft vasculopathy

B. Abadie1, C. Albert1, P. Bhat1, S. Harb1, M. Jacob1, R. Starling1, P. Cremer1, W.H. Tang1, W. Jaber1

1Cleveland Clinic Hospital, Cleveland, United States of America

Funding Acknowledgements: None.

Background: Positron emission tomography/computed tomography (PET/CT) is increasingly being used as an alternative to invasive coronary angiography for the detection of cardiac allograft vasculopathy (CAV) in heart transplant patients. The appropriate screening interval for patients with low-risk testing is unknown.

Purpose: The purpose of the study was to determine the number of patients with an initial-low risk PET/CT who progressed to a high-risk result with annual screening and what patient characteristics were associated with this progression.

Methods: Patients with heart transplant with no history of CAV 2/3 by angiography, whose initial PET/CT scan was low-risk, and who had a repeat PET/CT as part of an annual screening program were included in the study. A low-risk PET/CT was PET CAV score 0/1, and a high-risk PET/CT was PET CAV score 2/3, as defined by a previously published and validated diagnostic algorithm. The primary outcome was the percentage of patients who progressed to a high-risk result.

Results: The median time between PET/CT scans was 382 days (IQ 365 – 443). Only 2/163 (1.2%) patients with initial PET/CAV 0 progressed to PET CAV 2/3 on their repeat study compared to 7/37 (19%) for those with PET CAV 1 (RR 9.16, 95CI 2.97 – 28.29). During the study period, there were 0 episodes of urgent revascularization and 1 elective revascularization.

Conclusions: The risk of developing PET CAV 2/3 in patients with an initial result of PET CAV 0 is low at one year and annual screening may be unnecessary. Conversely, in patients initially classified as PET CAV 1, the risk of progression to PET CAV 2/3 is high and more frequent screening may be indicated.